PRGN-3007

PRGN-3007 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed using Precigen's UltraCAR-T platform. It is engineered with a single multicistronic transposon plasmid to simultaneously express a CAR targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), membrane-bound interleukin–15 (mbIL15) for enhanced in vivo expansion and persistence, a kill switch for safety, and an intrinsic blockade of programmed cell death protein 1 (PD-1) gene expression to overcome immune checkpoint inhibition. The therapy uses Precigen’s nonviral gene delivery system and overnight decentralized manufacturing process. Its primary indications have included hematological malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, as well as solid tumors like triple-negative breast cancer.